Fennec settles PEDMARK patent litigation; Cipla barred from generic until 2033

FENNEC PHARMACEUTICALS INC.

Lawsuit dismissed; each party bears its own costs.
Cipla agrees not to launch generic sodium thiosulfate in U.S. until September 1, 2033, subject to earlier entry under specified circumstances.
Settlement covers Cipla's ANDA for generic PEDMARK, resolving litigation in D.N.J.
Press release issued March 16, 2026 announcing the agreement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.